Drug Trial Radar · NCT06900010
A Study to Evaluate CM336 in Adults With Autoimmune Bullous Disease
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Apr 22, 2025
Primary completion
Jan 1, 2027
Study completion Jan 1, 2028
Sponsor
- Lead sponsor
- Shandong First Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Moderate to Severe Autoimmune Bullous Disease
Conditions
- Autoimmune Bullous Disease
Interventions
CM336 InjectionBiological
subcutaneous CM336 administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the efficacy after CM336 treatmentTime frame: Up to 52 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dermatology Hospital of Shandong First Medical University
Jinan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.